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Abstract 
Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease of unknown aetiology 
usually requiring long-term immunosuppressive therapy. We present the case of an AIH 
patient who received long-term corticosteroids and azathioprine. As treatment for 
concomitant osteoporosis she was also treated with potent intravenous bisphosphonate 
(BP). This treatment was complicated by the development of BP-related osteonecrosis of the 
jaw (BRONJ). BRONJ is an uncommon complication of BP treatment regimes that occurs at 
increased frequency in the presence of other risk factors, including chronic inflammatory 
conditions. Our patient suffered from a severe and complicated clinical course of BRONJ 
which, despite adequate therapy, resulted in death of the patient. Here we discuss the risk 
factors for the development and clinical course of BRONJ in AIH and the implications for 
management of these patients. 
 
Introduction 
Autoimmune hepatitis (AIH) is a relatively uncommon chronic autoimmune liver 
disease of unknown aetiology. It can present at all ages and in both sexes, affecting 
women more frequently than men (4:1) [1]. The incidence and point prevalence of AIH 
in Northern Europe are 1.9 and 16.9 per 100,000, respectively [2]. The presentation of 
AIH ranges from asymptomatic liver test abnormalities to acute liver failure. AIH is 
characterised by hyperimmunoglobulinaemia and the presence of autoantibodies 
(smooth muscle antibodies, anti-nuclear antibodies, liver-kidney microsomal 
antibodies and/or soluble liver/liver-pancreas antibodies) in the serum [1]. Typical 
histological features in liver biopsy include interface hepatitis and plasmacellular  
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infiltrates [1]. So far there is no single diagnostic test for AIH and due to the 
heterogenic presentation diagnosis may often be delayed in patients with otherwise 
unexplained transaminase abnormalities. In succession of the rather complex 1999 
diagnostic AASLD criteria, a simplified scoring system was devised for practical and 
clinical use by Hennes et al. in 2008 [3, 4]. Untreated AIH has an overall 5-year 
mortality of >50%, due to development of cirrhosis-related oesophageal variceal 
bleeding and liver failure [1]. Induction therapy with initial high-dose corticosteroids is 
therefore warranted in a majority of patients, and this induces remission in up to 90% 
after 6 months [1]. A large proportion of patients with medication-induced remission 
requires long-term maintenance therapy because of high relapse rates upon tapering of 
corticosteroids. These regimens consist of either low-dose corticosteroids (5 mg/day) 
or replacement therapy with azathioprine (1–2 mg/kg/day) [1]. 
AIH patients are prone to develop osteoporosis, which is most likely due to several 
factors. These include prolonged corticosteroid exposure and, because of impaired 
synthetic hepatic function, high unconjugated bilirubin and impaired conversion of 
vitamin D to 25-hydroxy vitamin D [5, 6]. For this reason, bisphosphonate (BP) 
treatment is widely used in these patients [5]. A rare complication of this preventative 
form of treatment is BP-related osteonecrosis of the jaw (BRONJ) [7]. BRONJ is 
characterised by spontaneous occurrence of an osseous, necrotic lesion of either the 
mandible or maxilla in BP-treated patients. This results in an open connection of the 
necrotic lesion with the oral cavity [7]. We discuss here the case of an AIH patient who 
developed BRONJ with a particularly severe clinical course, which resulted in death of 
the patient. 
Case Report 
A 75-year-old woman presenting with decompensated liver cirrhosis was diagnosed with AIH. 
Although remission was initiated with prednisone and azathioprine therapy, liver function tests 
including bilirubin (28–61 μmol/l) remained elevated for more than 1 year after the start of 
treatment. Despite several tapering and replacement therapy attempts, she remained corticosteroid 
dependent (>7.5 mg/day). At the time of diagnosis she underwent a bone mineral density (BMD) scan 
showing osteoporosis of the hip (BMD: 0.64 g/cm2; T score: –2.5; z score: –0.9). To prevent further 
progression of osteoporosis, she was initially treated with intravenous pamidronate 60 mg every 
3 months, together with vitamin D and calcium supplementation. Initially this did not have an effect 
on BMD. However, her BMD increased when she was switched to once a year infusions of 5 mg 
zoledronic acid.  
After 3 years of intravenous BP therapy she developed malnutrition due to eating difficulties as a 
result of severe pain in the jaw. She was therefore admitted to our hospital. Examination of the jaw 
revealed that this was due to an infected necrotic mandibular bone, which had an open connection 
with the oral cavity. Computed tomography later confirmed multifocal osteonecrosis of the mandible 
(fig. 1, fig. 2). Given the BP use and the absence of any known other cause she was diagnosed with 
BRONJ and therefore subsequently treated with analgesics and prophylactic antibiotics. This did 
not prevent progression of the osteonecrotic infection, from which Pseudomonas aeruginosa and 
Candida albicans were cultured. She subsequently underwent repeated mandibular sequestrectomy 
and tooth extraction. Despite intense therapy she eventually succumbed to respiratory failure due to 
disseminated C. albicans pneumonia.   
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Discussion 
BRONJ development is mainly associated with long-term, high-dose intravenous 
BP regimens for the treatment of bone involvement of malignancies [7]. In these 
patients incidence rates up to 12% have been reported after more than 3 years of BP 
therapy, but it may occur already after 4 months in these patients [8, 9]. Following 
FDA approval, potent low-dose BP agents are increasingly used in the treatment of 
osteoporosis [7]. While the occurrence in this patient category is substantially lower, 
BRONJ can develop in these patients as our case demonstrates. 
Treatment of symptomatic BRONJ lesions consists of analgesic therapy and 
antibiotics [7]. Depending on the severity of symptoms and the extension of the BRONJ 
lesions, debridement and sequestrectomy are indicated. These interventions generally 
give good results, but refractory cases have been described [7]. Discontinuation of 
intravenous BP therapy does not provide benefits in the short term, but may be 
beneficial in the long term [7]. Since food intake can be severely impaired by the 
inability to chew and swallow, adequate intake should be cared for to prevent 
malnutrition, if necessary by feeding through a nasogastric tube. 
So far, the pathogenesis of BRONJ is incompletely understood. It has been proposed 
that BP therapy may contribute to the development of osteonecrosis of the jaw through 
the inhibition of osteoclast function, impaired angiogenesis and mucosal ulceration 
[7, 10, 11]. Furthermore, bacterial overgrowth and infection have been implicated in 
the development of BRONJ lesions [12]. The pro-inflammatory response against 
bacteria prevents healing of the lesion, which can again serve as an entry port for 
prolonged bacterial infection [12]. BP agents can also induce a pro-inflammatory 
immune response in BRONJ lesions, disrupting the mucosal barrier [12]. Autoimmune 
diseases like AIH show a similar inflammatory profile and may theoretically contribute 
to the development of these osteonecrotic lesions [12–14].  
Immunosuppressive therapy as treatment for autoimmune diseases often 
includes systemic corticosteroids. Corticosteroid therapy itself increases the risk of 
osteonecrosis through vascular growth inhibition and osteoblastic apoptosis [13]. 
Therefore it is likely that corticosteroids may have an independent effect on the 
development of osteonecrosis of the jaw. Furthermore, immunosuppressive treatment 
increases the chances of oral bacterial overgrowth and thus may further increase the 
risk of infection of the jaw lesion. Concomitant use of immunosuppressants and potent 
BP agents therefore requires careful follow-up [7]. If BRONJ occurs, temporary 
discontinuation of immunosuppressants must be considered to enable the lesion to 
heal.  
AIH may significantly contribute to BRONJ development in case of poor hepatic 
synthetic function, as high unconjugated and conjugated bilirubin levels are associated 
with decreased osteoblast viability and increased osteoclastogenesis [6]. The latter 
effect may be neutralized by potent BP agents, thus critically interfering with bone 
remodelling in the jaw.  
Taken together, the above-mentioned factors may pose a particularly high risk for 
the development of BRONJ in patients with AIH. When starting BP treatment for the 
prevention of osteoporosis, we advise monitoring synthetic hepatic function and  
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replacing corticosteroid therapy if possible. In case of BRONJ development, besides 
standard care, cessation of immunosuppressive therapy should be considered and the 
nutrition status should be guarded. 
 
 
 
 
 
 
Fig. 1. Spiral computed tomography in the bone window setting of the mandible after sequestrectomy 
and tooth extraction. Note the bilateral cortical bone defects (arrows) suggestive of multifocal 
osteonecrosis in the mandibular body in the multiplanar reconstructions in axial (a), coronal (b) and 
sagittal (c) orientations. 
 
 
 
Fig. 2. Three-dimensional reconstruction of spiral computed tomography of the mandible using 
volume rendering technique. Note the extensive cortical defects of the mandible (arrows) suggestive 
of osteonecrosis. 
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